TY - JOUR
T1 - Update on rare epithelial ovarian cancers
T2 - Based on the rare ovarian tumors young investigator conference
AU - Jang, Ji Yon Agnes
AU - Yanaihara, Nozomu
AU - Pujade-Lauraine, Eric
AU - Mikami, Yoshiki
AU - Oda, Katsutoshi
AU - Bookman, Michael
AU - Ledermann, Jonathan
AU - Shimada, Muneaki
AU - Kiyokawa, Takako
AU - Kim, Byoung Gie
AU - Matsumura, Noriomi
AU - Kaku, Tsunehisa
AU - Kuroda, Takafumi
AU - Nagayoshi, Yoko
AU - Kawabata, Ayako
AU - Iida, Yasushi
AU - Kim, Jae Weon
AU - Quinn, Michael
AU - Okamoto, Aikou
N1 - Publisher Copyright:
© 2017. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology.
PY - 2017
Y1 - 2017
N2 - There has been significant progress in the understanding of the pathology and molecular biology of rare ovarian cancers, which has helped both diagnosis and treatment. This paper provides an update on recent advances in the knowledge and treatment of rare ovarian cancers and identifies gaps that need to be addressed by further clinical research. The topics covered include: low-grade serous, mucinous, and clear cell carcinomas of the ovary. Given the molecular heterogeneity and the histopathological rarity of these ovarian cancers, the importance of designing adequately powered trials or finding statistically innovative ways to approach the treatment of these rare tumors has been emphasized. This paper is based on the Rare Ovarian Tumors Conference for Young Investigators which was presented in Tokyo 2015 prior to the 5th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG).
AB - There has been significant progress in the understanding of the pathology and molecular biology of rare ovarian cancers, which has helped both diagnosis and treatment. This paper provides an update on recent advances in the knowledge and treatment of rare ovarian cancers and identifies gaps that need to be addressed by further clinical research. The topics covered include: low-grade serous, mucinous, and clear cell carcinomas of the ovary. Given the molecular heterogeneity and the histopathological rarity of these ovarian cancers, the importance of designing adequately powered trials or finding statistically innovative ways to approach the treatment of these rare tumors has been emphasized. This paper is based on the Rare Ovarian Tumors Conference for Young Investigators which was presented in Tokyo 2015 prior to the 5th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG).
UR - http://www.scopus.com/inward/record.url?scp=85020634557&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85020634557&partnerID=8YFLogxK
U2 - 10.3802/jgo.2017.28.e54
DO - 10.3802/jgo.2017.28.e54
M3 - Review article
C2 - 28541641
AN - SCOPUS:85020634557
SN - 2005-0380
VL - 28
JO - Journal of Gynecologic Oncology
JF - Journal of Gynecologic Oncology
IS - 4
M1 - e54
ER -
